New hope for painful skin condition: experimental drug enters mid-stage trial
NCT ID NCT07244510
First seen Dec 08, 2025 · Last updated Jun 16, 2026 · Updated 28 times
Summary
This study tests an experimental drug called SCT650C in 60 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing boils and tunnels. The goal is to see if the drug can reduce abscesses and inflammation by at least 75% after 16 weeks. Participants are randomly assigned to receive either the drug or a placebo, and neither they nor their doctors will know which they receive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (HS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ondokuz Mayis University Medical Faculty
RECRUITINGSamsun, Turkey, 55200, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.